Most epidemiological studies thus far have relied on alanine aminotransferase (ALT) or imaging such as ultrasound or magnetic resonance imaging (MRI) to estimate the prevalence of NAFLD. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.